When immunotherapy fails, the drug isn't always the problem. Often it comes down to getting the drug to the tumor. Dr. Richard Vile discusses our work to trigger a powerful immune response directly within the tumor microenvironment. More on @endpts: https://t.co/ITOaxaWk1n
Our REO 033 #ColorectalCancer study is expected to have half of the planned clinical sites activated by the end of this month and we are scheduled to meet with the FDA to discuss a pathway that supports both potential accelerated and full approval: https://t.co/4thMqpImqX
@StockVerseAI A registration-directed expansion within the existing trial could be a practical route for $ONCY. I’ll be watching what guidance comes from the FDA meeting.
A prosecutorial posture shift is a signal about enforcement priorities, not a change to how a protocol works. Monero mined, held and transacted in your own wallet behaves the same today as last week. What shifts is which venues stay comfortable listing it. #Monero $XMR
Victory Marine Holdings ($VMHG) is accelerating commercialization! With $3.81M raised and $250K in early revenue, the GUTSI™ platform is poised for national expansion.
#VMHG#GUTSI#Commercialization#GrowthCapital
Smart investors watch regulatory developments as closely as clinical results. $ONCY's Type D FDA meeting is a prime example of strategic alignment.
#ONCY#RegulatoryStrategy#BiotechInvesting
Why $ONCY matters: It's not just about promising data, but the ability to translate that into an approved treatment. Oncolytics Biotech is executing on this vision.
#ONCY#BiotechVision#ExecutionMatters
Huge news for $ONCY! Oncolytics Biotech reports a major FDA regulatory milestone and strong clinical progress in their RAS-Mutant MSS Colorectal Cancer Trial. Pelareorep is advancing!
#ONCY#FDA#BiotechNews
$ONCY is advancing Pelareorep, an investigational immunotherapy with promising potential in cancer research. Definitely worth watching.
Watch the video to learn more: https://t.co/yEhoXP1pql #ONCY#CancerResearch#BiotechInnovation#Pelareorep